| Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities |
21 |
| PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin |
21 |
| Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells |
15 |
| Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status |
15 |
| Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma |
14 |
| Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations |
13 |
| PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3 |
11 |
| Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences |
11 |
| Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects |
10 |
| Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives |
10 |
| NONMEM Tutorial Part II: Estimation Methods and Advanced Examples |
10 |
| Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women |
10 |
| Translational Assessment of Drug-Induced Proximal Tubule Injury Using a Kidney Microphysiological System |
10 |
| PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants |
9 |
| NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis |
9 |
| Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation |
9 |
| Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections |
9 |
| Modeling Composite Assessment Data Using Item Response Theory |
9 |
| Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations |
9 |
| Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance |
9 |
| Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next Level |
8 |
| First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates |
8 |
| Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine |
8 |
| Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities |
8 |
| Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction |
8 |
| Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients |
8 |
| A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition |
8 |
| Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam |
7 |
| Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics |
7 |
| Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape |
7 |
| Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative |
7 |
| Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label |
7 |
| Quantitative Systems Pharmacology: A Regulatory Perspective on Translation |
7 |
| Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction |
7 |
| Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans |
7 |
| A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors |
6 |
| Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities |
6 |
| Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers |
6 |
| Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network |
6 |
| Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial |
5 |
| Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling |
5 |
| A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors |
5 |
| A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate |
5 |
| Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
5 |
| Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema |
5 |
| Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators |
5 |
| Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments |
5 |
| Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology |
5 |
| Mathematical Biology Models of Parkinson's Disease |
5 |
| Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling |
5 |
